Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide

Annals of Oncology

Volumn 11, Issue 9, 2000, Pages 1127-1130

  Ricci, S ^a   Antonuzzo, A ^a   Galli, L ^a   Ferdeghini, M ^a   Bodei, L ^a   Orlandini, C ^a   Conte, P F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Depot lanreotide; Neuroendocrine tumors; Octreotide LAR

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; BILIRUBIN; CHORIONIC GONADOTROPIN ALPHA SUBUNIT; CREATININE; ENOLASE; GASTRIN; OCTREOTIDE; PANCREAS POLYPEPTIDE; SEROTONIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLOW RELEASE FORMULATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CHROMOGRANIN A; CHROMOGRANINS; DELAYED-ACTION PREPARATIONS; DIARRHEA; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; PERITONEAL NEOPLASMS; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0033783951     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008383132024     Document Type: Article

References (20)

1. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
2. Cloning and characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney
3. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylcyclase
4. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR) and fifth (hSSTR) human somatostatin receptor subtype
5. Detection of somatostatin receptors in surgical and percutaneous needle biopy samples of carcinoids and islet cell carcinomas
6. 111 In-DTPA-D-Phe1 - Octreotide scintigraphy in patients with carcinoid tumors: The predictive value for somatostatin analogue treatment
7. Octreotide
8. Subtype selective induction of wilde-type p-53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3
9. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide
10. Treatment of the carcinoid syndrome with long-acting somatostatin analogue lanreotide: A prospective study in 39 patients
11. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
12. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors
13. Sandostatin LAR: Pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients
14. Effects of intramuscolar microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients
15. Efficacy, tolerability and safety of Sandostatin LAR in acromegalic patients: Results of a multicentre study
16. Long-term therapy with long-acting octreotide (Sandostatin LAR) for the management of acromegaly
17. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome
18. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
19. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors
20. Pharmacokinetics and efficacy of a long acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly